PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶:

A61K 7/48

A1

(11) International Publication Number: WO 98/00103

(43) International Publication Date: 8 January 1998 (08.01.98)

(21) International Application Number: PCT/EP97/02691

(22) International Filing Date: 16 May 1997 (16.05.97)

60/020,744 28 June 1996 (28.06.96) US

(71) Applicant (for AU BB CA GB GH IE IL KE LC LK LS MN MW NZ SD SG SZ TT UG only): UNILEVER PLC [GB/GB]; Unilever House, Blackfriars, London EC4P 4BQ (GB).

(71) Applicant (for all designated States except AU BB CA GB
GH IE IL KE LC LK LS MN MW NZ SD SG SZ TT
UG): UNILEVER N.V. [NL/NL]; Weena 455, NL-3013
AL Rotterdam (NL).

(72) Inventors: ZNAIDEN, Alexander, Paul; 110 Fox Road, Trumbull, CT 06611 (US). CROTTY, Brian, Andrew; 46 Damascus Road, Branford, CT 06405 (US). JOHNSON, Anthony, William; 211 Papermill Lane, Fairfield, CT 06430 (US).

(74) Agent: ROTS, M., J., F.; Unilever plc, Patent Division, Colworth House, Sharnbrook, Bedford, MK44 1LQ (GB).

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: VITAMIN C DELIVERY SYSTEM

(57) Abstract

(30) Priority Data:

A cosmetic composition is provided which includes ascorbic acid (Vitamin C) solubilized by a cross-linked non-emulsifying siloxane elastomer in a carrier medium of a volatile siloxane. Aesthetic properties are also improved by the presence of the cross-linked non-emulsifying siloxane elastomer.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	Fi	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxemboure	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	T.J	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Paso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	77	Trinidad and Tobago
BJ	Benin	Œ	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazit	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	iceland	MW	Malawi	US	United States of Americ
CA	Canada	IТ	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Vict Nam
CG	Congo	KE	Келуа	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	2W	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ.	New Zealand	ZW.	Zimonowe
CM	Cameroon		Republic of Korea	PL.	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakatan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD.	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG SG			
			DIDGI IB	30	Singapore		

- 1 -

VITAMIN C DELIVERY SYSTEM

5 BACKGROUND OF THE INVENTION

Field of the Invention

The invention relates to a cosmetic product that can stably store ascorbic acid and then deliver same to the skin.

The Related Art

15

20

25

30

35

Ascorbic acid, also known by its common name of Vitamin C, has long been recognized as an active substance benefiting skin appearance. Vitamin C reportedly increases the production of collagen in human skin tissue. Wrinkles and fine lines are thereby reduced. An overall healthier and younger-looking appearance results. Vitamin C has also found utility as an ultraviolet ray blocking or absorbing agent. Whitening or bleaching skin compositions have also employed Vitamin C utilizing its property of interference with the melanin formation process. There also is a belief that ascorbic acid interacts with the human immune system to reduce sensitivity to skin aggravating chemicals. Reduced levels of Vitamin C concentration on the skin have also been implicated with an increase in stress. From all of the foregoing perspectives, Vitamin C or ascorbic acid may provide significant benefit when topically applied.

Unfortunately, Vitamin C is a very unstable substance.

Although it is readily soluble in water, rapid oxidation occurs in aqueous media. Solubility of ascorbic acid has

been reported to be relatively poor in nonaqueous media, thereby preventing an anhydrous system from achieving any significant level of active concentration.

- The art has sought to overcome the problem in a variety of ways. One approach is the preparation of ascorbic acid derivatives. These derivatives have greater stability than the parent compound and, through biotransformation or chemical hydrolysis, can at the point of use be converted to the parent acid. For instance, U.S. Patent 5,137,723 (Yamamoto et al) and U.S. Patent 5,078,989 (Ando et al) provide glycosylate and ester derivatives, respectively.
- U.S. Patent 4,818,521 (Tamabuchi) describes under the background technology a so-called two-pack type cosmetic wherein Vitamin C powder and other ingredients are separately packaged in different containers with mixing just prior to use of the cosmetic. The mixing procedure and expensive packaging were said to be drawbacks of this system. The patent suggests stable oil-in-water type emulsions that are weakly acidic and wherein ascorbic acid has been premixed with a stabilizing oil.
- Maintenance of pH below about 3.5 has also been suggested in U.S. Patent 5,140,043 (Darr et al) as a stabilization means for aqueous compositions of ascorbic acid.
- Water compatible alcohols such as propylene glycol, polypropylene glycol and glycerol have been suggested as co-carriers alongside water to improve stability. An illustration of this approach can be found in U.S. Patent 4,983,382 (Wilmott and Znaiden). Therein a blend of water and water-miscible organic solvent are combined as a stabilizing system. At least about 40% of the organic solvent must be ethanol while the remainder may be

5

selected from such alcohols as propylene glycol, glycerin, dipropylene glycol and polypropylene glycol.

Japanese Patent 44-22312 (Shionogi) describes the stabilization of Vitamin C in a mainly aqueous medium by a variety of glycols. These include polyethylene glycol, ethylene glycol, diethylene glycol and even ethanol. These formulations are intended for ingestion.

- 10 U.S. Patent 4,372,874 (Modrovich) has reported incorporation of relatively large amounts of ascorbic acid in a polar water-miscible organic solvent such as dimethyl sulfoxide. Levels of water are kept below 0.5% through addition of a particulate desiccant to the carrier.

 15 Although highly polar systems such as dimethyl sulfoxide
- may be effective, this and related carriers are toxicologically questionable.
- Accordingly, it is an object of the present invention to provide a delivery system for ascorbic acid in which the compound is miscible and hydrolytically and oxidatively storage stable.
- Another object of the present invention is to provide a delivery system which assists the penetration of ascorbic acid into the human skin while avoiding irritation thereof.
- Still another object of the present invention is to provide a system for delivering ascorbic acid that is aesthetically pleasing and imparts a soft and smooth skinfeel.
- These and other objects of the present invention will become more readily apparent through the following summary, detailed discussion and Examples.

SUMMARY OF THE INVENTION

A cosmetic composition is provided that includes:

- 5 (i) from 0.001 to 50% of ascorbic acid;
 - (ii) from 0.1 to 30% of a crosslinked non-emulsifying siloxane elastomer; and
- 10 (iii) from 10 to 80% of a volatile siloxane.

DETAILED DESCRIPTION OF THE INVENTION

- Now it has been discovered that ascorbic acid can be stabilized against decomposition and also stably suspended in a system containing a crosslinked non-emulsifying siloxane elastomer and a volatile siloxane.
- Ascorbic acid is available from several sources including Roche Chemicals. Amounts of this material may range from 0.001 to 50%, preferably from 0.1 to 10%, optimally from 1 to 10% by weight.
- Crosslinked non-emulsifying siloxane elastomers of this invention will have an average number molecular weight in excess of 10,000, preferably in excess of 1,000,000 and optimally will range from 10,000 to 20 million. The term "non-emulsifying" defines a siloxane from which
- polyoxyalkylene units are absent. Preferably the crosslinked non-emulsifying siloxane elastomer is formed from a divinyl monomer reacting with Si-H linkages of a siloxane backbone. Illustrative of the elastomer is a material with the CTFA name of Crosslinked Stearyl Methyl-Dimethyl
- 35 Siloxane Copolymer, available as Gransil SR-CYC (25-35% active elastomer) from Grant Industries, Inc., Elmwood

WO 98/00103 PCT/EP97/02691

- 5 -

Park, New Jersey. Supply of related elastomer may also be available from the General Electric Company.

Amounts of the elastomer may range from 0.1 to 30%, preferably from 1 to 15%, optimally from 3 to 10% by weight.

5

10

15

25

35

A third essential element of the present invention is that of a volatile siloxane. Illustrative of this category are the cyclo polydimethyl siloxane fluids of the formula [(CH₁)₂SiO)]₂, wherein x denotes an integer of from 3 to 6. The cyclic siloxanes will have a boiling point of less than 250°C and a viscosity at 25°C of less than 10 centipoise. Cyclomethicone is the common name of such materials. The tetramer and pentamer cyclomethicones are commercially available as DC 244 and DC 344 from the Dow Corning Corporation.

Amounts of the volatile siloxane will range from 10 to 80%, preferably from 20 to 70%, optimally from 30 to 65% by weight.

Compositions of this invention may further include a pharmaceutically acceptable carrier. Generally the carrier will be an ingredient which can solubilize Vitamin C and all other elements of the composition. Amounts of the carrier may range from 1 to 70%, preferably from 10 to 60%, optimally from 20 to 50% by weight.

Pharmaceutically acceptable carriers may be selected from water, polyols, silicone fluids, esters and mixtures thereof. When present, water may range from 0.5 to 20%, preferably from 1 to 10%, usually from 2 to 6%, optimally less than 5% by weight of the composition.

Advantageously one or more polyols are present as carriers in the compositions of this invention. Illustrative are propylene glycol, dipropylene glycol, polypropylene glycol, polypropylene glycol, polyethylene glycol, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-butylene glycol, 1,2,6-hexanetriol, glycerin, ethoxylated glycerin, propoxylated glycerin and mixtures thereof. Most preferably the polyol is a mixture of polyethylene glycol, molecular weight ranging from 200 to 2,000, and propylene glycol.

Preferred weight ratios of polyethylene glycol to propylene glycol range from 5:1 to 1:10, preferably from 2:1 to 1:5, optimally 1:1 to 1:2. Amounts of the polyol may range from 1 to 50%, preferably from 10 to 40%, optimally from 25 to 35% by weight of the composition.

15

20

25

30

35

5

Silicone oils may also be included as carriers in the compositions of this invention. These oils will be The nonvolatile silicone oils useful in the nonvolatile. compositions of this invention are exemplified by the polyalkyl siloxanes, polyalklyaryl siloxanes and polyether siloxane copolymers. The essentially nonvolatile polyalkyl siloxanes useful herein include, for example, polydimethyl siloxanes with viscosities of from about 5 to about 100,000 centistokes at 25°C. Such polyalkyl siloxanes include the Viscasil series (sold by General Electric Company) and the Dow Corning 200 series (sold by Dow Corning Corporation). Polyalkylaryl siloxanes include poly(methylphenyl)siloxanes having viscosities of from about 15 to about 65 centistokes at 25°C. These are available, for example, as SF 1075 methylphenyl fluid (sold by General Electric Company) and 556 Cosmetic Grade Fluid (sold by Dow Corning Corporation). Useful polyether siloxane copolymers include, for example, a polyoxyalkylene ether copolymer having a viscosity of about 1200 to 1500 centistokes at 25°C. Such a fluid is available as SF-1066 organosilicone surfactant (sold by

5

25

General Electric Company). Cetyl dimethicone copolyol and cetyl dimethicone are especially preferred because these materials also function as emulsifiers and emollients. The former material is available from Goldschmidt AG under the trademark Abil EM-90. Amounts of the nonvolatile siloxane may range from 0.1 to 40%, preferably from 0.5 to 25% by weight of the composition.

Esters may also be incorporated into the cosmetic compositions as pharmaceutically acceptable carriers.

Amounts may range from 0.1 to 50% by weight of the composition. Among the esters are:

- atoms. Methyl, isopropyl, and butyl esters of fatty acids are useful herein. Examples include hexyl laurate, isohexyl laurate, isohexyl palmitate, isopropyl palmitate, decyl oleate, isodecyl oleate, hexadecyl stearate, decyl stearate, isopropyl isostearate, diisopropyl adipate, diisohexyl adipate, dihexyldecyl adipate, diisopropyl sebacate, lauryl lactate, myristyl lactate, and cetyl lactate.

 Particularly preferred are C12-C15 alcohol benzoate esters.
 - (2) Alkenyl esters of fatty acids having 10 to 20 carbon atoms. Examples thereof include oleyl myristate, oleyl stearate, and oleyl oleate.
- 30 (3) Ether-esters such as fatty acid esters of ethoxylated fatty alcohols.
- (4) Polyhydric alcohol esters. Ethylene glycol mono and di-fatty acid esters, diethylene glycol mono- and di-fatty acid esters, polyethylene glycol (200-6000) mono- and di-fatty acid esters, propylene glycol

mono- and di-fatty acid esters, polypropylene glycol 2000 monooleate, polypropylene glycol 2000 monostearate, ethoxylated propylene glycol monostearate, glyceryl mono- and di-fatty acid esters, polyglycerol poly-fatty esters, ethoxylated glyceryl monostearate, 1,3-butylene glycol monostearate, 1,3-butylene glycol distearate, polyoxyethylene polyol fatty acid ester, sorbitan fatty acid esters, and polyoxyethylene sorbitan fatty acid esters are satisfactory polyhydric alcohol esters.

- (5) Wax esters such as beeswax, spermaceti, myristyl myristate, stearyl stearate.
- (6) Sterols esters, of which cholesterol fatty acid esters are examples thereof.

Minor adjunct ingredients may also be included in cosmetic compositions of this invention. These ingredients may be selected from preservatives, fragrances, anti-foam agents, opacifiers, colorants and mixtures thereof, each in their effective amounts to accomplish their respective functions.

25

5

10

15

The following examples will more fully illustrate the embodiments of this invention. All parts, percentages and proportions referred to herein and in the appended claims are by weight unless otherwise indicated.

30

EXAMPLE 1

The effect of a crosslinked non-emulsifying siloxane elastomer was evaluated by comparing the experimental and control formulations outlined under Table I.

- 9 -

TABLE I
Test Formulations

COMPONENT	Example No.	(Weight %)
	1	1A (CONTROL)
Cyclomethicone	36.0	60.0
Gransil SR CYL	24.0	
Polyethylene Glycol 200	19.25	19.25
Dimethyl Isosorbide	10.0	10.0
Ascorbic Acid	5.0	5.0
Sodium Chloride	1.0	1.0
Cetyl Dimethicone Copolyol	0.8	0.8
Water	4.0	4.0

15

10

Formulation 1 was a homogeneous stable aesthetically pleasing emulsion of cream-like consistency. By contrast, formulation 1A did not form an emulsion.

20

25

EXAMPLES 2-5

A series of further examples were prepared. Their compositions are outlined under Table II. These formulations provide good storage stability for the ascorbic acid and are aesthetically consumer acceptable.

30

TABLE II

COMPONENT	I	Example No	. (Weight %	6)
	2	3	4	5
Cyclomethicone	42.0	41.6	40.0	42.0
Gransil SR CYL	18.0	17.9	17.3	18.0
Propylene Glycol	16.8	14.8	17.5	15.0
Polyethylene Glycol 200	11.0	13.7	13.5	13.5
Ascorbic Acid	5.0	5.0	5.0	5.0
Dimethyl Isosorbide	2.0	2.0	2.0	2.0
Cetyl Dimethicone Copolyol	0.8	0.8	0.8	0.8
Water	balance	balance	balance	balance

EXAMPLES 6-12

These series of Examples illustrate the scope of the present invention. Various concentrations of ascorbic acid, cyclomethicone and siloxane elastomer are illustrated.

5

10

15

- 11 -

TABLE III

	COMPONENT	Example No. (Weight %)						
		6	7	8	9	10	11	12
5	Cyclomethi- cone	36.0	36.0	36.0	40.0	40.0	45.0	32.0
	Gransil SR CYL	24.0	24.0	24.0	20.0	20.0	15.0	27.0
10	Butylene Glycol	17.5		17.5				29.0
	Glycerin		17.5					
	Polyethylene Glycol 200	10.0			17.5	12.0	10.0	10.0
15	Polyethylene Glycol 800	- -	10.0	10.0	10.0	12.0	10.0	
	Dimethyl Isosorbide	2.0	2.0	2.0	4.0	8.0	10.0	1.0
	Ascorbic Acid	1.0	1.0	1.0	4.0	4.0	8.0	0.5
20	Cetyl Dimethicone Copolyol	0.8	0.8	0.8	0.8	0.8		
	Water	bal.	bal.	bal.	bal.	bal.	bal.	bal.

25

30

The foregoing description and Examples illustrates elected embodiments of the present invention. In light thereof variations and modifications will be suggested to one skilled in the art, all of which are within the spirit and purview of this invention.

CLAIMS

1.	Α	cosmetic	composition	comprising:
----	---	----------	-------------	-------------

5

- (i) from 0.001 to 50% of ascorbic acid;
- (ii) from 0.1 to 30% of a crosslinked nonemulsifying siloxane elastomer; and

10

- (iii) from 10 to 80% of a volatile siloxane.
- The composition according to claim 1 wherein the crosslinked non-emulsifying siloxane elastomer is formed from a divinyl monomer reacting with the Si-H linkages of a siloxane backbone.
 - 3. The composition according to claim 1 or claim 2 wherein the volatile siloxane is cyclomethicone.

INTERNATIONAL SEARCH REPORT

Inter nal Application No PCT/EP 97/02691

A. CLASS IPC 6	IFICATION OF SUBJECT MATTER A61K7/48		
According (to International Patent Classification (IPC) or to both national cl.	assification and IPC	
B. FIELDS	S SEARCHED	· · · · · · · · · · · · · · · · · · ·	
IPC 6	focumentation searched (classification system followed by classification s	ication symbols)	
Documenta	tion searched other than minimum documentation to the extent the	nat such documents are included in the fields :	searched
Electronic o	data hase consulted during the international search (name of data	hase and, where practical, search terms used)	
C. DOCUM	MENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of th	e relevant passages	Relevant to claim No.
A	DATABASE WPI Section Ch, Week 9244 Derwent Publications Ltd., Lond Class A26, AN 92-360690	lon, GB;	1
	XP002041754 & JP 04 261 111 A (KANEBO LTD) September 1992 see abstract	, 17	
Α,	FR 2 715 844 A (L'OREAL) 11 Aug see examples	pust 1995	1,3
A	EP 0 669 126 A (L'OREAL) 30 Aug see claims 1-5; examples	just 1995	1,3
A	GB 1 161 289 A (HOFFMANN-LA ROC 13 August 1969 * see the whole document *	CHE & CO.)	1
Furt	ther documents are listed in the continuation of box C.	X Palent family members are listed	in annex.
* Special ca	tegories of cited documents :	- The Land down and multiplicate of the second	lamahunal filma data
consid	nent defining the general state of the art which is not lered to be of particular relevance	"T" later document published after the in- or priority date and not in conflict w cited to understand the principle or t invention	ith the application but
liling of the common that the	ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another	e claimed invention It be considered to ocument is taken alone claimed invention	
"O" docum other i		"Y" document of particular relevance; the cannot be considered to involve an in document is combined with one or in ments, such combination being obvious in the art.	nventive step when the nore other such docu-
	ent published prior to the international filing date but han the priority date claimed	"&" document member of the same paten	t family
Date of the	actual completion of the international search	Date of mailing of the international s	earch report
2	5 September 1997	1 3. 10. 97	
Name and i	mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2	Authorized officer	
	NI 2280 EFV Rajswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+ 31-70) 340-3016	McConnell, C	

INTERNATIONAL SEARCH REPORT

information on patent family members

Inter 1al Application No PCT/EP 97/02691

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR 2715844 A	11-08-95	CA 2141765 A EP 0670157 A JP 7256086 A US 5552446 A US 5629004 A	05-08-95 06-09-95 09-10-95 03-09-96 13-05-97
EP 0669126 A	30-08-95	FR 2715563 A CA 2141373 A US 5605694 A	04-08-95 01-08-95 25-02-97
GB 1161289 A	13-08-69	BE 717214 A CH 509302 A DE 1300555 B DE 1793234 A FR 1600826 A NL 6808139 A,B SE 354185 B US 3873713 A	27-12-68 30-06-71 25-05-72 03-08-70 31-12-68 05-03-73 25-03-75